Friday, May 20, 2016

3 New Drugs for Fibromyalgia on the Way?


(91outcomes.com) - A new article discussed in detail three new drugs that could be on the way for fibromyalgia.  Fibromyalgia, a condition with chronic widespread pain at its core, is a presumptive for Veterans Affairs disability claims for veterans with Persian Gulf service from 1990 to the present.


The new drugs that could prove beneficial for fibromyalgia sufferers include:


  • IMC-1, "a combination of famciclovir (Famvir), a common antiviral, with celecoxib (Celebrex), an anti-inflammatory arthritis drug," for an FDA-cleared Phase III clinical trial in 2017.
  • Microgabalin (DS-5565), "which relieves pain by binding to the body’s calcium channels," but, with, "a unique binding profile and long duration of action at voltage gated calcium channels."
  • Tonmya (TNX-102 SL), a new under-the-tongue formulation of cyclobenzaprine HCL 2.8 mg to improve sleep quality, and, it is hoped thereby, other fibromyalgia symptoms.


Read the full, very well written article by Donna Gregory Burch for the National Pain Report, at:  http://nationalpainreport.com/three-new-fibromyalgia-drugs-could-be-on-the-way-8830514.html

New Study Shows Epigenetic Changes in Gulf War Toxin Rat Model

The study on which these findings are based was funded by the treatment-focused Gulf War Illness Research Program (GWIRP), within the Congressionally Directed Medical Research Program (CDMRP) administered by the U.S. Department of Defense health program.

Most notably, according to the study's findings, "Results from this study implicate a role for epigenetic alterations in GWI."